BUZZ-Protagonist Therapeutics jumps on S&P SmallCap addition

Reuters06-28

** Shares of Protagonist Therapeutics up 10.3% premarket to $35.16, a 2-week high, as co set to join S&P SmallCap 600 index next week

** Biotech firm to replace Encore Wire in SPCY prior to market open Weds, Jul 3, according to S&P Dow Jones Indices

** Encore being acquired by Italian cablemaker Prysmian

in $4.2 bln deal

** PTGX's lead product candidates are rusfertide, for treatment of a rare blood disease, and psoriasis drug, JNJ-2113, which it's developing in collaboration with Johnson & Johnson

** Through Thurs close, PTGX shares up 39% YTD giving co ~$1.9 bln market cap, per LSEG

** All 6 analysts covering the stock are bullish, including 2 "strong buy" ratings; median PT is $45 - LSEG

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@thomsonreuters.com lance.tupper@tr.com 1-646-279-6380))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment